2.Early application of tacrolimus extended-release capsule after kidney transplantation
Zhiyu ZOU ; Song CHEN ; Sheng CHANG ; Linrui DAI ; Ziwen PAN ; Qianqian ZHANG ; Yuanyuan YANG ; Yibo HOU ; Renjie CHEN ; Chenzhen YU ; Weijie ZHANG
Organ Transplantation 2023;14(2):257-
Objective To evaluate the efficacy and safety of tacrolimus extended-release (Tac-ER) in the early stage after kidney transplantation. Methods Clinical data of 68 recipients undergoing kidney transplantation from 34 pairs of renal allografts were retrospectively analyzed. Two recipients who received bilateral kidneys from the same donor were treated with Tac-ER (Tac-ER group) and tacrolimus immediate-release (Tac-IR) (Tac-IR group) as one of the basic immunosuppressant. The changes of tacrolimus dosage and blood concentration, intra-patient variability (IPV), renal function, incidence of acute rejection, recipient and allograft survival rates and adverse events were statistically compared between two groups. Results The average daily dose of tacrolimus in the Tac-ER group was significantly higher than that in the Tac-IR group (